IP Library › Granted Patent US 12,091,418
Granted Patent B2
US 12,091,418 · App. 18/495,455 · Granted Sep 17, 2024

Anti-tumor compound and preparation method and use thereof

Inventors: Yu Zhang (Shanghai, CN); Zhongyuan Zhu (Shanghai, CN); Haiqing Hua (Shanghai, CN); Bing Li (Shanghai, CN); Jian Li (Shanghai, CN); Shengchao Lin (Shanghai, CN); Xi Li (Shanghai, CN); Hongxia Shen (Shanghai, CN)
Assignee: DUALITY BIOLOGICS (SUZHOU) CO., LTD.
C07D491/22A61K47/65A61K47/6803A61K47/6855A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,091,418
App. No.
18/495,455
Granted
Sep 17, 2024
Kind
B2
Abstract

The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.

Claims (11)

1. An antibody-drug conjugate having the following structure:

or a pharmaceutically acceptable salt thereof, wherein n is the connection number, and n is selected from the group consisting of 1 to 10.

2. The antibody-drug conjugate or pharmaceutically acceptable salt thereof according to claim 1 , wherein n is 6 to 8.

3. The antibody-drug conjugate or pharmaceutically acceptable salt thereof according to claim 2 , wherein n is 7.

4. The antibody-drug conjugate or pharmaceutically acceptable salt thereof according to claim 2 , wherein n is 8.

5. The antibody-drug conjugate or pharmaceutically acceptable salt thereof according to claim 1 , wherein trastuzumab comprises a light chain comprising an amino acid sequence set forth in SEQ ID NO: 33, and a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 37.

6. A pharmaceutical composition comprising an antibody-drug conjugate or pharmaceutically acceptable salt thereof of claim 1 , or a mixture thereof, and a pharmaceutically acceptable carrier or diluent.

7. A method of treating cancer in a subject in need thereof, comprising administering to said subject the antibody-drug conjugate or pharmaceutically acceptable salt thereof of claim 1 .

8. The method of claim 7 , wherein the cancer is selected from the group consisting of lung cancer, kidney cancer, urinary tract carcinoma, colorectal cancer, prostatic cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer and esophageal cancer.

9. The method of claim 8 , wherein the cancer is selected from the group consisting of breast cancer and stomach cancer.

10. The antibody-drug conjugate or pharmaceutically acceptable salt thereof according to claim 2 , wherein n is 6.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2023
From: ZHANG, YU; ZHU, ZHONGYUAN; HUA, HAIQING; LI, BING; LI, JIAN; LIN, SHENGCHAO; LI, XI; SHEN, HONGXIA
To: DUALITY BIOLOGICS (SUZHOU) CO., LTD.
Reel/Frame 065980/0711 →
Priority Claims (1)
CN 202011061580.7 · Sep 30, 2020 · national
Continuity (4)
Continuation 18187935 · Mar 22, 2023
Continuation 17825090 · May 26, 2022
Continuation PCTCN2021121721 · Sep 29, 2021
Related Publication 20240132516A1 · Apr 25, 2024
Cited By (1)
US 12,434,077